Patents by Inventor Kyle Jacoby

Kyle Jacoby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
    Patent number: 12247061
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 11, 2025
    Assignee: ADOC SSF, LLC
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Homology directed repair compositions for the treatment of hemoglobinopathies
    Patent number: 12110499
    Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: October 8, 2024
    Assignee: Seattle Children's Hospital
    Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
  • HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240124896
    Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 18, 2024
    Applicants: Seattle Children's Hospital (d/b/a Seattle Children's Research Institute), Fred Hutchinson Cancer Center
    Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY
    Publication number: 20240066063
    Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a modified TGF?RII expression.
    Type: Application
    Filed: May 18, 2023
    Publication date: February 29, 2024
    Applicant: PACT PHARMA, INC.
    Inventors: Charles W. TRAN, John D. Gagnon, Barbara Sennino, Stefanie Mandl-Cashman, Kyle Jacoby, William Lu, Michael Mayne Dubreuil, James S. Byers, III, Michal Mass, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING NEXT GENERATION ENGINEERED T CELL THERAPY
    Publication number: 20230355762
    Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a secondary Payload in an expression construct.
    Type: Application
    Filed: April 25, 2023
    Publication date: November 9, 2023
    Applicant: PACT PHARMA, INC.
    Inventors: Michal Mass, William Lu, Kyle Jacoby, Michael Mayne Dubreuil, Barbara Sennino, Stefanie Mandl-Cashman, James S. Byers, III
  • MICROBIAL CONSORTIA
    Publication number: 20230165913
    Abstract: The present disclosure provides microbial consortia comprising O. formigenes capable of stable engraftment in the gastrointestinal tract of a subject and methods of using and making the same.
    Type: Application
    Filed: December 1, 2022
    Publication date: June 1, 2023
    Applicant: Federation Bio, Inc.
    Inventors: Lee Robert Swem, Pawan Kumar, Aditya Bhalla, Shital A. Tripathi, Anupreet Parmar, Joshua J. Hamilton, Ariel R. Brumbaugh, Dante P. Ricci, Hans Richard William Layman, Ariana M. Ciglar, James Berleman, Zachary Walters, Kyle Jacoby, Nicholas D. Youngblut, Andreas Grauer, Emily Drabant Conley, Heather Romasko
  • METHODS OF DETERMINING GENE EDITING EFICIENCIES IN CELLS
    Publication number: 20230136076
    Abstract: Methods of detecting the efficacy and presence of a biologic drug which uses one or more 2A peptide in its manufacture and/or final pharmaceutical formulation.
    Type: Application
    Filed: October 24, 2022
    Publication date: May 4, 2023
    Applicant: Pact Pharma, Inc.
    Inventors: Kyle JACOBY, Barbara Sennino, Susan Foy, Theresa L. Hunter
  • LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID
    Publication number: 20230054471
    Abstract: Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 23, 2023
    Inventors: Andrew M. Scharenberg, Kyle Jacoby, Alexandra E. Grier
  • Long poly(A) plasmids and methods for introduction of long poly(A) sequences into the plasmid
    Patent number: 11400169
    Abstract: Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 2, 2022
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: Andrew M. Scharenberg, Kyle Jacoby, Alexandra E. Grier
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20220193139
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
    Patent number: 11304978
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 19, 2022
    Assignee: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES
    Publication number: 20220010274
    Abstract: Methods of genetically engineering NeoTCR Products comprising young T cells and methods of manufacturing such cell products.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 13, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Susan Foy, Ines Mende, Stefanie Mandl-Cashman
  • PRIMARY CELL GENE EDITING
    Publication number: 20210395783
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 23, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • HOMOLOGY-DIRECTED REPAIR TEMPLATE DESIGN AND DELIVERY TO EDIT HEMOGLOBIN-RELATED MUTATIONS
    Publication number: 20210309995
    Abstract: Some embodiments of the methods and compositions provided herein relate to modifying hemoglobin loci, such as hemoglobin-related mutations including sickle cell mutations. Some embodiments relate to modification of a sickle cell mutation through introduction of a phosphodiester DNA strand break at the site of the sickle cell mutation.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 7, 2021
    Inventors: David J. Rawlings, Sowmya Pattabhi, Andrew M. Scharenberg, Kyle Jacoby
  • HOMOLOGY DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20210222201
    Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
    Type: Application
    Filed: April 24, 2018
    Publication date: July 22, 2021
    Inventors: Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TET2 ENGINEERED T CELL THERAPY
    Publication number: 20210085720
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a knockout of the expression of the TET2 gene.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20210085721
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • METHODS OF PERFORMING GUIDE-SEQ ON PRIMARY HUMAN T CELLS
    Publication number: 20210062248
    Abstract: Disclosed herein are methods for identifying the effects, including off target effect, of genomic modification of primary cells. These methods are performed with high accuracy suitable for validating therapeutic T-cell engineering approaches.
    Type: Application
    Filed: August 26, 2020
    Publication date: March 4, 2021
    Applicant: PACT Pharma Inc.
    Inventors: Xiaoyan Robert Bao, Kyle Jacoby, William Lu
  • PRIMARY CELL GENE EDITING
    Publication number: 20200299730
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Primary cell gene editing
    Patent number: 10711283
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: July 14, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff